Yi Chai

Dr. Yi Chai

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Addiction
Verified
Journal Article
Closed access
PDF file
YCYi Chai
Yi Chai
HLHao Luo
Hao Luo
YWYue Wei
Yue Wei
SCSherry Kit Wa Chan
Sherry Kit Wa Chan
KMKenneth K. C. Man
Kenneth K. C. Man
ECEsther W Chan
Esther W Chan

28 May 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
HLHao Luo
Hao Luo
MKMarjaana Koponen
Marjaana Koponen
CRChristoph Roethlein
Christoph Roethlein
CBCornelia Becker
Cornelia Becker
JBJ. Simon Bell
J. Simon Bell
IWIan Chi Kei Wong
Ian Chi Kei Wong
Background Information on the survival of people living with dementia over time and across systems can help policymakers understand the real-world impact of dementia on health and social care systems. This multinational cohort study examines the trends in relative mortality risk following a dementia diagnosis. Methods A common protocol was applied to population-based data from the UK, Germany, Finland, Canada (Ontario), New Zealand, South Korea, Taiwan and Hong Kong. Individuals aged 60+ with an incident dementia diagnosis recorded between 2000 and 2018 were followed until death or the end of the study period. Cox proportional hazards regression was used to assess the association of mortality in dementia patients with the year of dementia diagnosis. Results Data from 1,272,495 individuals, with the mean age at diagnosis ranging from 76.8 years (South Korea) to 82.9 years (Germany), show that the overall median length of survival following recorded diagnosis ranges from 2.4 years (New Zealand) to 7.9 years (South Korea). Hazard ratios (HRs) estimated from Cox proportional hazard models decline consistently over the study period in the UK, Canada, South Korea, Taiwan and Hong Kong, which accounted for 84% of all participants. For example, the HR decreases from 0.97 (95% CI: 0.92–1.02) in 2001 to 0.72 (0.65–0.79) in 2016 in comparison to year 2000 in the UK. Conclusions This study shows a steady trend of decreasing risk of mortality in five out of eight databases, which signals the potential positive effect of dementia plans and associated policies and provides reference for future policy evaluation.

5 December 2024 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
YHYuqi Hu
Yuqi Hu
LGLe Gao
Le Gao
LZLingyue Zhou
Lingyue Zhou
WLWenlong Liu
Wenlong Liu
CWCuiling Wei
Cuiling Wei
FLFrancisco Lai
Francisco Lai
Background: Clozapine is widely regarded as a highly efficacious psychotropic drug that is largely underused worldwide. Recent disproportionality analyses and nationwide case-control studies suggested a potential association between clozapine use and hematological malignancy (HM). Nevertheless, the absolute rate difference is not well-established due to the absence of analytic cohort studies. The clinical significance of such a potential risk remains unclear. Methods and findings: We extracted data from a territory-wide public healthcare database from January 2001 to August 2022 in Hong Kong to conduct a retrospective cohort study of anonymized patients aged 18+ years with a diagnosis of schizophrenia who used clozapine or olanzapine (drug comparator with highly similar chemical structure and pharmacological mechanisms) for 90+ days, with at least 2 prior other antipsychotic use records within both groups. Weighted by inverse probability of treatment (IPTW) based on propensity scores, Poisson regression was used to estimate the incidence rate ratio (IRR) of HM between clozapine and olanzapine users. The absolute rate difference was also estimated. In total, 9,965 patients with a median follow-up period of 6.99 years (25th to 75th percentile: 4.45 to 10.32 years) were included, among which 834 were clozapine users. After IPTW, the demographic and clinical characteristics of clozapine users were comparable to those of olanzapine users. Clozapine users had a significant weighted IRR of 2.22 (95% confidence interval (CI) [1.52, 3.34]; p < 0.001) for HM compared to olanzapine users. The absolute rate difference was estimated at 57.40 (95% CI [33.24, 81.55]) per 100,000 person-years. Findings were consistent across subgroups by age and sex. Sensitivity analyses all supported the robustness of the results and showed good specificity to HM but no other cancers. The main limitation of this observational study is the potential residual confounding effects that could have arisen from the lack of randomization in clozapine or olanzapine use. Conclusions: Absolute rate difference in HM incidence associated with clozapine is small despite a 2-fold elevated rate. Given the rarity of HM and existing blood monitoring requirements, more restrictive indication for clozapine or special warnings may not be necessary.

4 March 2024 in Epidemiology and Psychiatric Sciences
Verified
Journal Article
Open access
PDF file
YCYi Chai
Yi Chai
KMKenneth K. C. Man
Kenneth K. C. Man
HLHao Luo
Hao Luo
CTCarmen Olga Torre
Carmen Olga Torre
YWYun Kwok Wing
Yun Kwok Wing
IWIan Chi Kei Wong
Ian Chi Kei Wong
Aims: Population-wide restrictions during the COVID-19 pandemic may create barriers to mental health diagnosis. This study aims to examine changes in the number of incident cases and the incidence rates of mental health diagnoses during the COVID-19 pandemic. Methods: By using electronic health records from France, Germany, Italy, South Korea and the UK and claims data from the US, this study conducted interrupted time-series analyses to compare the monthly incident cases and the incidence of depressive disorders, anxiety disorders, alcohol misuse or dependence, substance misuse or dependence, bipolar disorders, personality disorders and psychoses diagnoses before (January 2017 to February 2020) and after (April 2020 to the latest available date of each database [up to November 2021]) the introduction of COVID-related restrictions. Results: A total of 629,712,954 individuals were enrolled across nine databases. Following the introduction of restrictions, an immediate decline was observed in the number of incident cases of all mental health diagnoses in the US (rate ratios (RRs) ranged from 0.005 to 0.677) and in the incidence of all conditions in France, Germany, Italy and the US (RRs ranged from 0.002 to 0.422). In the UK, significant reductions were only observed in common mental illnesses. The number of incident cases and the incidence began to return to or exceed pre-pandemic levels in most countries from mid-2020 through 2021. Conclusions: Healthcare providers should be prepared to deliver service adaptations to mitigate burdens directly or indirectly caused by delays in the diagnosis and treatment of mental health conditions.

17 October 2025 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
CHCaige Huang
Caige Huang
YYYu Yang
Yu Yang
YWYue Wei
Yue Wei
VYVincent K.C. Yan
Vincent K.C. Yan
KLKyung Jin Lee
Kyung Jin Lee
ECEsther W Chan
Esther W Chan
The availability of psychotropic medications serves as a key indicator of global mental health status, underscoring the critical importance of continued monitoring. However, comprehensive studies assessing the global effect of the COVID-19 pandemic on such trends remain lacking. This study aimed to describe psychotropic consumption trends before and after the onset of the COVID-19 pandemic and investigate the pandemic's short- and long-term effects on psychotropic consumption across 91 countries and regions. This study used country-level sales data of psychotropic medications between Q1, 2012, and Q2, 2023 of 91 countries and regions from the IQVIA-Multinational Integrated Data Analysis System. Average annual sales trends were estimated and expressed as defined daily dose per 1000 inhabitants per day (DDD/TID) at the overall level and stratified by medication class and country income level. Relative average annual changes were assessed for the periods 2017–2019 and 2020–2022 both overall and within specific medication classes and income groups. The pandemic's short- and long-term effects on psychotropic medication sales were examined through interrupted time series analyses using quarterly data, conducted for each country and at overall level. Globally, the total consumption of psychotropic medications increased from 34.12 DDD/TID in 2020 to 36.15 DDD/TID in 2022, corresponding to a relative average increase of 2.94% [95% CI 0.97, 4.94] annually. The estimated relative change during 2020–2022 were 1.82% [1.02, 2.64] in Lower-Middle-Income-Countries (LMICs), 6.77% [−0.39, 14.45] in Upper-Middle-Income-Countries (UMICs), and 2.48% [0.72, 4.27] in High-Income-Countries (HICs). Overall psychotropic consumption showed an initial surge in Q1 2020 (level change: 1.94 DDD/TID [1.67, 2.21]), followed by a rapid decline during Q2 2020 (level change: −1.03 [−1.52, −0.54]). Most HICs exhibited a similar pattern. Following the pandemic onset, there was an increasing trend in overall psychotropic consumption (trend change: 0.13 [0.07, 0.19]). 70 of 91 countries showed an increasing slope change. Psychotropic medication consumption increased globally after the onset of the COVID-19 pandemic. During the pandemic, consumption rates in LMICs and UMICs appeared to slow down, however, patterns of change in psychotropic medication consumption following onset of the pandemic vary on a country level. To address these disparities, strategies for equitable psychotropic medication distribution and enhanced mental health care access in LMICs and UMICs are needed to improve global mental health. None.

26 September 2023 in Communications Medicine
Verified
Journal Article
Open access
PDF file
YCYi Chai
Yi Chai
RCRachel Yui Ki Chu
Rachel Yui Ki Chu
YHYuqi Hu
Yuqi Hu
ILIvan Chun Hang Lam
Ivan Chun Hang Lam
FCFranco Wing Tak Cheng
Franco Wing Tak Cheng
FLFrancisco Lai
Francisco Lai
Background: Preclinical evidence suggests that certain antipsychotic medications may inhibit the development of lung cancer. This study aims to investigate the association between incident lung cancer and different cumulative exposure periods of flupentixol or any antipsychotics. Methods: Using electronic health records from the Hospital Authority in Hong Kong, this nested case-control study included case participants aged 18 years or older with newly diagnosed lung cancer after initiating antipsychotics between January 1, 2003, and August 31, 2022. Each case was matched to up to ten controls of the same sex and age, who were also antipsychotic users. Multivariable conditional logistic regression models were conducted to quantify the association between lung cancer and different cumulative exposure times of flupentixol (0–365 days [ref]; 366–1825 days; 1826+ days) and any antipsychotics (1–365 days [ref]; 366–1825 days; 1826+ days), separately. Results: Here we show that among 6435 cases and 64,348 matched controls, 64.06% are males, and 52.98% are aged 65–84 years. Compared to patients with less than 365 days of exposure, those with 366–1825 days of exposure to flupentixol (OR = 0.65 [95% CI, 0.47–0.91]) and any antipsychotics (0.42 [0.38–0.45]) have a lower risk of lung cancer. A decreased risk is observed in patients who have 1826+ days of cumulative use of any antipsychotics (0.54 [0.47–0.60]). Conclusions: A reduced risk of lung cancer is observed in patients with more than one year of exposure to flupentixol or any antipsychotics. Further research on the association between lung cancer and other antipsychotic agents is warranted.